BioSpace News Archive

Levita Magnetics, whose mission is to expand patient access to advanced surgical care, today celebrates a key advancement in minimally invasive surgery with the deployment of its MARS surgical system at a North Texas-based hospital.

Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor.

Allarity Therapeutics, Inc. today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”).

Spineology ® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales.

FibroBiologics, Inc. announced today data from its latest study in a diabetes mouse model on the potential therapeutic efficacy of dermal fibroblast spheroids in treating chronic wounds.

The global oncology clinical trials market size was valued at USD 13.19 billion in 2023 and is projected to reach USD 22.11 Billion by 2033, growing at a CAGR of 5.3 % from 2024 to 2033. North America dominated the market and accounted for the largest revenue share of 43% in 2023.

RaySearch Laboratories AB will present the latest software innovations at IBA’s International Symposium on Proton Therapy in Boston, Massachusetts, April 5, and at the National Proton Conference run by the National Association on Proton Therapy in Boston, April 6-9.

Emboline, Inc. announced the acquisition of a significant portfolio of key intellectual property from SWAT Medical AB for aortic embolic protection during interventional cardiology procedures.

The Assignee of Civetta Therapeutics, LLC, a trailblazer in the field of biotechnology with a focus on β-propeller protein research, is inviting bids for the company’s rich portfolio of intellectual property.

iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for ECUR-506 in Ornithine Transcarbamylase (OTC) deficiency.